Evidence map›Paper›PMID 28851317›Full record

Trial reportBMC nephrology2017

The dynamics of the metabolism of acetate and bicarbonate associated with use of hemodialysates in the ABChD trial: a phase IV, prospective, single center, single blind, randomized, cross-over, two week investigation.

William B Smith, Sandy Gibson, George E Newman, Kendra S Hendon, Margarita Askelson, James Zhao, Jamil Hantash, Brigid Flanagan, John W Larkin, Len A Usvyat and 2 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IVRandomized Controlled Trial
In one paragraph

Trial report in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02334267 (Acid-Base Composition With Use of hemoDialysates), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02334267 nacompletednot on this map

Acid-Base Composition With Use of hemoDialysates: the ABChD Trial

TypeinterventionalSponsorFresenius Medical Care North AmericaRan2014 to 2015Enrolled11ConditionsEnd Stage Renal DiseaseArmsGroup 1: GranuFlo, Group 2: NaturaLyte
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

William B SmithVolunteer Research Group and New Orleans Center for Clinical Research at the University of Tennessee Medical Center, 1928 Alcoa Highway, Suite 107, Knoxville, TN, 37920, USA. wbsmd@noccr.com.
Sandy GibsonVolunteer Research Group and New Orleans Center for Clinical Research at the University of Tennessee Medical Center, 1928 Alcoa Highway, Suite 107, Knoxville, TN, 37920, USA.
George E NewmanKnoxville Kidney Center, PLLC, 320 Park 40 N Blvd, Knoxville, TN, 37923, USA.
Kendra S HendonKnoxville Kidney Center, PLLC, 320 Park 40 N Blvd, Knoxville, TN, 37923, USA.
Margarita AskelsonEDETEK, 500 College Road East, Suite 200, Princeton, NJ, 08540, USA.
James ZhaoEDETEK, 500 College Road East, Suite 200, Princeton, NJ, 08540, USA.
Jamil HantashTandem Labs, 115 Silvia Street, West Trenton, NJ, 08628, USA.
Brigid FlanaganFrenova Renal Research, 920 Winter Street, Waltham, MA, 02451, USA.
John W LarkinFresenius Medical Care North America, 920 Winter Street, Waltham, MA, 02451, USA.
Len A UsvyatFresenius Medical Care North America, 920 Winter Street, Waltham, MA, 02451, USA.
Ravi I ThadhaniMassachusetts General Hospital Division of Nephrology, 55 Fruit Street #1008, Boston, MA, 02114, USA.
Franklin W MadduxFresenius Medical Care North America, 920 Winter Street, Waltham, MA, 02451, USA.
Fresenius Medical Care North America (United States)Alcoa (United States) · USFresenius Medical Care (United States) · USMassachusetts General Hospital · USRenal Research Institute · USTandem Diabetes Care (United States) · USVolunteer Research Group and New Orleans Center for Clinical Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the United States, hemodialysis (HD) is generally performed via a bicarbonate dialysate. It is not known if small amounts of acid used in dialysate to buffer the bicarbonate can meaningfully contribute to overall buffering administered during HD. We aimed to investigate the metabolism of acetate with use of two different acid buffer concentrates and determine if it effects blood bicarbonate concentrations in HD patients.

methodsThe Acid-Base Composition with use of hemoDialysates (ABChD) trial was a Phase IV, prospective, single blind, randomized, cross-over, 2 week investigation of peridialytic dynamics of acetate and bicarbonate associated with use of acid buffer concentrates. Eleven prevalent HD patients participated from November 2014 to February 2015. Patients received two HD treatments, with NaturaLyte® and GranuFlo® acid concentrates containing 4 and 8 mEq/L of acetate, respectively. Dialysate order was chosen in a random fashion. The endpoint was to characterize the dynamics of acetate received and metabolized during hemodialysis, and how it effects overall bicarbonate concentrations in the blood and dialysate. Acetate and bicarbonate concentrations were assessed before, at 8 time points during, and 6 time points after the completion of HD.

resultsData from 20 HD treatments for 11 patients (10 NaturaLyte® and 10 GranuFlo®) was analyzed. Cumulative trajectories of arterialized acetate were unique between NaturaLyte® and GranuFlo® (p = 0.003), yet individual time points demonstrated overlap without remarkable differences. Arterialized and venous blood bicarbonate concentrations were similar at HD initiation, but by 240 min into dialysis, mean arterialized bicarbonate concentrations were 30.2 (SD ± 4.16) mEq/L in GranuFlo® and 28.8 (SD ± 4.26) mEq/L in NaturaLyte®. Regardless of acid buffer concentrate, arterial blood bicarbonate was primarily dictated by the prescribed bicarbonate level. Subjects tolerated HD with both acid buffer concentrates without experiencing any related adverse events.

conclusionsA small fraction of acetate was delivered to HD patients with use of NaturaLyte® and GranuFlo® acid buffers; the majority of acetate received was observed to be rapidly metabolized and cleared from the circulation. Blood bicarbonate concentrations appear to be determined mainly by the prescribed concentration of bicarbonate.

trial registrationThis trial was registered on ClinicalTrials.gov on 11 Dec 2014 ( NCT02334267 ).

Indexed as

Renal DialysisAcetatesAcid-Base EquilibriumAdultAgedBicarbonatesCross-Over StudiesFemaleHemodialysis SolutionsHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesSingle-Blind MethodAcetatesBicarbonatesHemodialysis SolutionsAcetateAcid-BaseBicarbonateDialysateHemodialysisHemodynamicsMetabolism

Identifiers

PMID28851317
PMCPMC5576126
OpenAlexW2753435151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.